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STUDIES OF LIVER FUNCTION IN SUBJECTS RECEIVING METHOXSALEN*
DANIEL H. LABBY, M.D., J. DONALD IMBRIE, B.S. AND THOMAS B.
FITZPATRICK, M.D., Ph.D.
The chemical configuration of methoxsalen has
been somewhat disturbing to investigators inter-
ested in hepatic function because of possible
hepatotoxic activity. Some meager preliminary
data suggesting that selective damage might
occur was based on the finding of questionable
elevation of occasional cephalin-cholesterol floc-
culation tests. A systematic study of liver function
with methoxsalen seemed indicated particularly
in view of the projected widespread clinical trial
which has since taken place over the last several
months. Elliott in 1956, reporting on 22 patients
receiving the drug, stated that two developed
elevated bromsulphalein retention. Pretreatment
examinations of liver function were not available
so that the precise significance of these elevated
tests is uncertain.
Since our own concern with the problem stem-
med from an interest in metabolism with particu-
lar emphasis on liver function, we focused the
resources of our laboratory on the possibility that
methoxsalen might be hepatotoxic. In designing
this experiment the following tests of liver func-
tion were selected since they each have peculiar
advantages.
First, the bromsulphalein test was selected
because it is oue of our more sensitive indicators
of liver dysfunction in the absence of jaundice,
picking up early disturbances in function; it is
also reproducible and easily standardized. It is
fairly specific although there is some evidence
that peripheral uptake of the dye does occur.
Over a period of years, however, we have by now
been witness to more than ten thousand brom-
sulphalein examinations so that our confidence
in the clinical interpretation of this test is firmly
based.
The thymol and zinc turbidity tests, while
non-specific for liver function, are found to be
most often disturbed in the presence of liver
disease or injury. These turbidity tests are simple
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measurements of the cloudiness resulting when
saturated solutions of either zinc sulfate or
thymol are added to approximately 0.1 cc. of
serum. The resulting turbidity depends on the
presence of the precipitating agent (zinc or
thymol) and some lipoprotein which changes in
concentration in the serum during periods of
liver damage. In addition, there are changes in
gamma and beta globulin that reflect alterations
in liver function, the zinc test being particularly
associated with gamma globulin changes.
The cephalin-eholesterol flocculation test is a
sensitive screening test and was added to the
experiment because it reflects the diffuseness of
the hepatie lesion. In addition, it should be
emphasized that the tests singly mean very
little, but when all are done simultaneously the
resulting information is greatly enhanced in
value. Our laboratory is geared almost completely
for the study of liver function so that we have
the advantage of a long period of standardization
of procedures as well as long experienced technical
personnel.
In the present study 25 medical students were
selected and divided into two groups of 12 each.
One student was discarded because preliminary
testing revealed a 4 + cephalin flocculation test.
The 12 test subjects were randomly selected and
received daily one dose of 30 mg. of methoxsalen,
12 receiving the drug, and the 12 others received
placebos. The subjects and the physicians were
unaware of which drug was being used. (Dr.
Fowlks of our group detected fluorescence in the
sera of those patients receiving the drug, but he
did not know their names nor did those of us
involved know that Dr. Fowlks' serum tests were
revealing those subjects on drug or placebo at the
time the experiment was in progress.) All volun-
teers were in good state of nutrition and were
basically in good health.
Table 1 shows the results of the pre- and post-
treatment period on the serum eephalin-eholes-
terol flocculation tests. At the end of twenty-four
hours, the serum showed that eight of the 12 had
no flocculation, four had a 1 + reaction, etc. At
the end of 48 hours, 7 of the 12 were still zero,
and 2 had a 1+. The placebo group was no differ-
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TABLE I
Results of cephalin-cholesterol flocculation tests
performed at monthly intervals to compare 12
subjects taking placebos with 12 subjects taking
30 mg. methoxsalen per day
Cepholin—Cholesterol Flocculatior
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ent significantly since at the end of 24 hours 7
were zero, and at the end of 48 hours 5 had a zero,
etc. One month after starting therapy, 10 had a
zero, and at the end of 48 hours 10 were still
zero. At the end of 48 hours a 1 + appeared. There
were 2 + reactions in the drug group, and two 2 +
reactions also in the placebo group. At two
months the findings were not much different, and
at three months had changed not at all. I might
say that the normal limits in our laboratory go
to 2+, and one can see that there were no reac-
tions beyond this either in the placebo or drug-
treated group.
The thymol turbidity reactions have been
shown in Figure 1. Our normal limits are six
units or less, and during the control period one
can see that the ranges, according to the black
lines crossing the baseline, fall well within the
normal range. The open circles represent placebo
controls. While there is some variation in the
mean, it stays well within the normal range, but
over a period of three months and, indeed, at the
end of three months of therapy, the entire range
is well within the normal zone and the variation
is extremely small. The occasional instance of a
4.2 unit reading is still acceptably normal. Our
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Fm. 1. Means and extremes of thymol turbidity
reactions done at monthly intervals to compare
12 subjects taking placebos with 12 subjects taking
30 mg. methoxsalen per day.
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FIG. 2. Means and extremes of BSP retentions
performed on 12 subjects before and after inges-
tion of 30 mg. methoxsalen per day for three
months compared with BSP retention of 12 sub-
jects taking placebos.
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laboratory would not feel that tests of this order
of magnitude would be significant since they are
unsupported by aberrations in any of the other
tests. Clinical examinations done on these sub-
jects throughout the period of testing showed no
abnormalities.
The bromsulphalein examinations, summarized
in Figure 2, also show no abnormalities, and the
mean values fall within the middle zone of ac-
ceptable normal.
The zinc turbidity reactions (Figure 3) showed
little abnormality except for one single elevation
beyond accepted normal on one instance, but,
again, this was not reinforced by abnormalities
in the other tests.
Although 75 or 80 liver function tests are
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FIG. 3. Means and extremes of zinc turbidity
reactions performed at monthly intervals to com-
pare 12 subjects taking placebos with 12 subjects
taking 30 mg. methoxsalen per day.
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known, and any or all of them might have been
applied to this experiment, it seemed feasible for
practical considerations to select these few for
their unique characteristics and apply them in
combination. This reinforced the strength of our
experimental design considerably.
Clinically, there were only occasional periods
of epigastric distress. One, patient complained of
nasal distress, one vertigo, but otherwise no
extraordinary signs or symptoms developed. I
think it is also important to note that one group
received therapy in the early part of our winter
from October through December, and another
from December through February. This is the
period in Portland, Oregon, for the peak incidence
of hepatitis. Were there even slight amounts of
hepatie damage from the drug, creating possible
increased vulnerability to hepatitis, these were
not shown by the laboratory or clinical examina-
tions. Being medical students, of course, they
were exposed around the hospitals and clinics to
patients with diseases of all varieties. Secondly,
it is also of interest that this period of experimen-
tation coincided with the period of mid-term
and final semester examinations when bouts of
moderate alcoholism among medical students are
not unknown! All I can say is that in spite of
two possible stress experiences, there was no evi-
dence of liver dysfunction, and all tests stayed
well within normal limits.
These data then show that none of the 12
subjects receiving methoxsalen developed changes
in hepatic function. It is possible to state with
95% confidence only that no more than 27% of a
population like this group of subjects may de-
velop a change in liver function. These figures
have been evolved by the work of our biostatisti-
cians, especially Dr. Carl Hopkins and Dr.
Farrington Daniels, Jr., who have been interested
in the confidence values for an experiment
involving only 24 men. In other words, as they
have expressed it, anywhere from 100% to 73%
of individuals ingesting 30 mg. of methoxsalen
daily for three months will not have a change in
hepatic function as detected by the tests we have
used in this study. The small sample size limits
the sensitivity of the experiment, and it will not
allow a more positive statement. Our consultants
tell us that to be more certain of a negative effect
of a drug for 99% of the population would require
an experimental group of at least 450 subjects.
While I would not diminish the firm convictions
that arise from such statistical confidences, 'I
would like to think that our considerable practical
experience in the interpretation of liver tests in
the field of hepatic injury carries with it a more
favorable confidence factor—one that probably
does not lend itself easily to statistical expres-
sions.
